A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia
Advanced Science · 2025-08 · 12 (31)
DOI: 10.1002/advs.202505087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 31.05.2025. Verfasst von Ruinan Jia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China. Hauptthemen laut MEDLINE: Ferroptosis, Reactive Oxygen Species, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Amyloid Precursor Protein Secretases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Distinguished Taishan Scholars in Climbing Plan, Young Taishan Scholars, Key Technology R&D and S/T Benefiting the People Demonstration Project.
Abstract (Originalsprache)
T‐cell acute lymphoblastic leukemia (T‐ALL) is a highly aggressive hematological malignancy for which targeted therapies remain underdeveloped. Oncogenic mutations in Notch1 occur in up to 75% of T‐ALL patients. Although γ‐secretase inhibitors (GSIs) can block Notch1 activation, their clinical application is limited by side effects and reduced sensitivity. Here, a self‐assembling, reactive oxygen species (ROS)‐responsive nanotherapeutic strategy—PHD/G‐NPs—co‐loaded with GSI and controlled released dihydroartemisinin (DHA), and modified with a CD38 antibody is reported. The CD38 antibody specifically targets T‐ALL cells, while GSI selectively inhibits Notch1, resulting in a dual‐targeting approach. GSI is released first, inhibiting Notch1 activation and inducing the death of a subset of T‐ALL cells. To eliminate semi‐quiescent T‐ALL cells that escape initial therapy by elevating ROS levels, a ROS‐sensitive DHA delivery system is employed to enhance ferroptosis and boost GSI efficacy. After elucidating the mechanism of action of PHD/G‐NPs in T‐ALL cells, PHD/G‐NPs are combined with αPD‐1, which triggers an anti‐tumor immune response in vivo. This dual‐targeting strategy using CD38‐modified PHD/G‐NPs enables controlled drug release, enhances ferroptosis, mitigates GSI‐induced gastrointestinal toxicity, and improves therapeutic efficacy. This nanomedical approach offers a novel strategy for targeted T‐ALL treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China.
- NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology (Ministry of Education), Shandong Key Laboratory of Targeted Drug Delivery and Advanced Pharmaceutics, Depa…
- Cryomedicine Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong Province, 250012, China.
- Shandong Key Laboratory of Hematological Diseases and Immune Microenvironment, Qilu Hospital, Shandong University, Jinan, 250012, P. R. China.
ORCID-Profile: Chunyan Ji
Förderung
- Distinguished Taishan Scholars in Climbing Plan
- Young Taishan Scholars
- Key Technology R&D and S/T Benefiting the People Demonstration Project
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- China Postdoctoral Science Foundation
- Fundamental Research Funds for the Central Universities
- Independently Cultivate Innovative Teams of Jinan, Shandong Province
Zitieren
APA
Jia, R., Liu, Y., Xiao, J., Xia, Y., Zhao, X., Ma, H., Ye, J., Zhang, Z., Sun, T., & Ji, C. (2025). A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia. Advanced Science, 12(31). https://doi.org/10.1002/advs.202505087
Vancouver
Jia R, Liu Y, Xiao J, Xia Y, Zhao X, Ma H, et al. A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia. Advanced Science. 2025;12(31). doi:10.1002/advs.202505087
BibTeX
@article{Jia2025,
author = {Jia, Ruinan and Liu, Yang and Xiao, Jilong and Xia, Yuan and Zhao, Xin and Ma, Huixian and Ye, Jingjing and Zhang, Zhiyue and Sun, Tao and Ji, Chunyan},
title = {A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {31},
doi = {10.1002/advs.202505087}
}
EUVIMED